Skye stock plunged Monday after the biotech company scrapped its failed eye-disease drug in favor of pivoting to obesity treatment.

The post Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet appeared first on Investor’s Business Daily.